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Abstract - Although the genotype and subgenotype distribution of HBV isolates from Serbia has previously been reported, 
data about whole genome sequences from this area are scarce. This study included plasma samples from 5 chronically 
infected patients. Full genome amplification of the HBV isolates was performed by nested-PCR using 7 primer pairs, and 
the whole genome nucleotide sequences were obtained by direct sequencing. Two complete genome sequences belonged 
to D2 subgenotype (ayw3 HBsAg subtype), one to D1 (ayw2) and two to A2 (adw2). All 5 Serbian isolates clustered with 
sequences from the expected geographic regions and had nucleotide and coded protein length in accordance to their as-
signed genotypes, except for one HBeAg-negative isolate displaying G1896A mutation leading to a premature stop codon 
in the Pre-C region. The first complete genome sequences of HBV D1, D2 and A2 subgenotypes from Serbian patients 
showed characteristics similar to the nucleotide sequences of HBV isolates from other European and Middle East coun-
tries. 
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INTRODUCTION
Hepatitis B virus (HBV) is an important etiologic 
agent of acute or chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma. It is estimated that there 
are currently more than 350 million chronically in-
fected people worldwide.
Since  HBV  replication  involves  an  error-
prone reverse transcription step, the HBV genome 
evolves quickly over time, with an estimated nu-
cleotide substitution rate between 1.5 and 7.9 x 105 
substitution per site per year. This unique replica-
tion strategy accounts for the majority of the point 
mutations, deletions and insertions observed in the 
HBV genome. The lengthy evolution of HBV has 
led to the current existence of various genotypes, 
subgenotypes,  mutants,  recombinants,  and  even 
quasispecies  of  HBV  (Lee  and  Locarnini,  2004; 
Osiowy et al., 2006).
According to the homogeneity of virus sequenc-
es, 10 HBV genotypes (A to J) have been defined by 
divergence in the entire HBV genomic sequences 
of >8%. Except for the newly identified genotypes 
I and J, the geographic and ethnic distributions of 
HBV genotypes and subtypes are well character-
ized. Genotype A is predominant in northwestern 
Europe and North America; genotypes B and C are 
confined to the populations with origins in East-
ern Asia and the Far East (Okamoto et al., 1988); 
genotype D is found worldwide but prevails in the 
Mediterranean area and the Near and Middle East, 
extending into India (Norder et al., 2004., Amini-1320 IVANA LAZAREVIĆ ET AL.
Bavil-Olyaee et al., 2005); genotype E is indigenous 
to western sub-Saharan areas; genotype F is typi-
cal  for  American  natives  and  Polynesia  (Norder 
et al., 2004); genotype G has been reported in the 
USA, Germany and France (Stuyver et al., 2000); 
the eighth genotype, H (Arauz-Ruiz et al., 2002), is 
found in Central America and recently, genotype 
I (Phung et al., 2010), a novel inter-genotypic re-
combination was isolated in Vietnam and Laos; the 
newest HBV genotype, J (Tatematsu et al., 2009), 
was identified in Japan.
Further extensive phylogenetic analyses of the 
HBV  genotypes  have  resulted  in  recognition  of 
subgenotypes of genotypes A, B, C, D and F, based 
on more than 4% intragenotypic divergence (Nor-
der et al., 2004). To date, the presence of 7 subg-
enotypes has been recognized for HBV genotypes 
B and D (Sakamoto et al., 2007; Meldal et al., 2009), 
5 for genotypes A and C (Sakamoto et al., 2006; 
Olinger  et  al.,2006),  while  4  subgenotypes  have 
been reported for genotype F. The data about the 
number of new subgenotypes vary due to different 
taxonomic criteria and more epidemiological, viral 
and clinical features are still needed for some of the 
newly described subgenotypes to justify their clas-
sification. 
Serbia has an intermediate pattern of HBV in-
fection,  with  a  prevalence  of  HBsAg  positivity  of 
approximately 2-7% of the population, and mixed 
patterns of infant, early childhood and adult trans-
mission. Two HBV genotypes, A and D, and 4 subg-
enotypes A2, D1, D2, and D3 have been encountered 
in  Serbia,  with  genotype  D  and  subgenotype  D3 
being prevalent (Lazarević et al., 2010). So far, only 
three complete HBV genome sequences of subgeno-
type D3 from Serbian isolates have been published 
(Stanojević et al., 2011), while complete genome se-
quences of other subgenotypes circulating in Serbia 
have not yet been characterized.
The aim of the present study was to characterize 
the complete nucleotide sequences of HBV isolates 
of genotypes A and D from chronically infected pa-
tients in Serbia.
MATERIALS AND METHODS
The study included 5 plasma samples from patients 
with chronic hepatitis B, treated at the Clinics of In-
fectious and Tropical Diseases in Belgrade. The diag-
nosis was based on HBsAg positivity for >6 months 
and histopathological verification by liver biopsy. All 
patients had high viral loads (9.63-11.43 log copies/
mL) and all but one were HBeAg-positive. None re-
ceived any antiviral therapy prior to investigation. 
The HBeAg-positive and therapy-naïve patients were 
selected in order to avoid therapy- and immune-de-
rived  nucleotide  substitutions  within  the  genome. 
Based on the partial genome sequencing, 3 isolates 
belonged to genotype D, and 2 to genotype A. The 
demographic  and  viral  characteristics  of  the  pa-
tients/isolates are summarized in Table 1. The study 
was approved by the Ethics Committee of School of 
Medicine, University of Belgrade, and informed con-
sent to participate in this study was obtained from 
the patients.
HBV DNA from the plasma was extracted us-
ing QIAmp Blood Mini Kit (Qiagen GmBH, Hilden, 
Germany) according to the manufacturer’s instruc-
tions. DNA amplification was carried out by nested-
PCR, where primers F1 and R7 were used in the first 
round of PCR for amplification of the whole genome, 
and 7 primer pairs (Table 2.) were used in the second 
round of PCR for amplification of 7 partially overlap-
ping segments. The primers, previously described by 
Zhu et al. (2007), were adjusted for the best ampli-
fication of genotypes A and D, since these were the 
expected genotypes in the Serbian population. The 
amplification protocol included: initial denaturation 
for 5 min at 950C followed by 40 cycles of amplifica-
tion (940C for 40 s, 600C for 30 s and 720C for 4 min 
with a 30 s increase each five cycles for the first round 
PCR) and a 7 min final extension at 720C.
The PCR products were purified using the QIA-
GEN  MinElute  Purification  Kit  (Qiagen  GmBH), 
according to the manufacturer’s protocol. For cycle 
sequencing  reactions,  second  round  PCR  primers 
and a BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA) were used. Se-COMPLETE HBV GENOMES FROM SERBIA 1321
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Fig.1. Phylogenetic analysis of 5 complete HBV genome sequences from Serbia (srb176, srb200, srb205, srb207, srb210) compared with 
82 comparative complete genome sequences represented in the phylogenetic tree with subgenotype, Genbank accession numbers and 
country of origin. Bootstrap confidence values of ≥70% are given.COMPLETE HBV GENOMES FROM SERBIA 1323
quencing was carried out in an automatic sequencer 
(ABI PRISM 310 Genetic Analyzer; Applied Biosys-
tems). Sense and antisense strands were sequenced, 
compared and assembled. The 7 obtained sequences 
for each isolate were assembled into whole genome 
sequences in MEGA software version 3.1 (Kumar et 
al., 2004).
The nucleotide sequences were aligned pairwise 
using ClustalW, and a phylogenetic tree was con-
structed by the neighbor-joining method and Kimu-
ra two-parameter algorithm. Statistical significance 
of  phylogeny  was  estimated  by  bootstrap  analysis 
with 1,000 pseudoreplicate datasets. For comparison, 
reference  sequences  for  9  known  HBV  genotypes 
from the DDBJ/EMBL/GenBank database were used 
as well as more isolates of genotypes A and D from 
different parts of the world (total of 106: 4 for A1, 13 
for A2, 2 for A3, 3 for B, 5 for C, 24 for D1, 19 for D2, 
11 for D3, 3 for D4, 2 for D5, 3 for D6, D7, E, F, G, H 
and 2 for I).
The viral genotype and subgenotype were iden-
tified by phylogenetic analysis. The HBsAg subtype 
was deduced from the sequence by a previously de-
scribed algorithm (Purdy et al., 2007), which is based 
on identifying amino acids at positions 122 (Lys/Arg 
for d/y determinants), 160 (Lys/Arg for w/r determi-
nants), 127 (Pro/Thr/Leu-Ile for w2/w3/w4), and in 
the case of Arg122 Pro127 Lys160, also at positions 
159 (Ala/not Ala for ayw1/ayw2 and ayw4) and 140 
(not Ser/Ser for ayw2/ayw4).
The whole genome sequences were analyzed for 
the presence of clinically relevant mutations in the 
HBsAg, BCP (basal core promoter) region of the X 
gene, Pre-C and RT (reverse transcriptase) of the P 
gene in BioEdit (Hall, 1999) and MEGA software.
The nucleotide sequence data reported are avail-
able in the GenBank database under accession num-
bers: JQ687529-JQ687533.
RESULTS
The complete genome sequences of 5 isolates were 
analyzed and compared with 106 isolates of geno-
types A and D from different parts of the world and 
with reference sequences for 9 known HBV geno-
types from the DDBJ/EMBL/GenBank database. Two 
of the analyzed isolates belonged to genotype A, and 
3 to genotype D. Both genotype A isolates clustered 
with the representative sequence for the A2 subgen-
otype in the phylogenetic tree, whereas genotype D 
isolates belonged to two different subgenotypes: one 
to D1 and two to D2. The results are summarized in 
a phylogenetic tree, where only 82 comparative se-
quences are shown due to limited space (Fig. 1). All 
5 Serbian isolates clustered with sequences from ex-
pected geographic regions.
HBsAg  subtypes  were  deduced  from  the  se-
quence by identifying amino acids at positions 122, 
160, 127, 159, and 140. Both of the genotype A iso-
lates displayed a sequence characteristic for the adw2 
HBsAg subtype. As expected from known subgeno-
type/HBsAg subtype associations, the subgenotype 
D1 isolate belonged to ayw2, while both D2 isolates 
belonged to ayw3 (Table 1.). 
Both genotype A isolates showed the expected 
length of 3221 bp with a 6-nucleotide (nt) insert at the 
carboxyl terminus of the core gene (nt 2356-2361). 
All genotype D isolates (srb200, srb205 and srb207) 
showed the characteristic 33-nt deletion in the Pre-
S1 region (nt2859-2891) which corresponded to the 
spacer region of HBV polymerase gene. Accordingly, 
the deduced 7 proteins M, L, S of the Pre-S/S gene, 
P, X and Pre-C/C and C were 400, 281,226, 845, 154, 
214 and 185 aa long for genotype A isolates, and 389, 
281, 226, 832, 154, 212 and 183 aa for the genotype 
D isolates.
All isolates were examined for the presence of 
clinically relevant mutations in the HBsAg region, 
RT region of P gene, BCP region of X gene and Pre-
C region. A specific search was conducted for muta-
tions associated with resistance to nucleot(z)ide ana-
logues at positions 80, 166, 169, 173, 180, 181, 184, 
200, 204, 207, 215, 236 and 250 of the RT region, but 
despite detected minor changes in RT in all isolates 
(particularly in genotype D), none were found on the 1324 IVANA LAZAREVIĆ ET AL.
specified positions. The HBsAg region was examined 
for the presence of known mutations related to vac-
cine escape, immunotherapy resistance and diagnos-
tic failure. Changes T118A and P127T were found in 
2 isolates but were not regarded as mutations since 
they represent subgenotype/HBsAg subtype-depend-
ent polymorphisms (Tallo et al., 2008). Three more 
changes in this region (I110M, A159V, L193S) were 
registered in 4 isolates, all outside “ä” determinant. 
In the BCP region of the X gene, analysis included 
changes associated with the decreased production of 
HBeAg A1762T, G1764A and related compensatory 
mutations at positions 1753, 1766 and 1768. Only one 
genotype D isolate (srb200) displayed compensatory 
mutation T1753A in this region. Mutation G1896A 
of Pre-C region leading to stop codon and complete 
abolishment of HBeAg production was detected in 
another genotype D isolate (srb205). 
DISCUSSION
Serbia’s geographic position on the main route be-
tween the Middle East and Central Europe and in 
close proximity to the Mediterranean basin has in-
fluenced HBV genotype and subgenotype distribu-
tion. As previously described, two genotypes were 
encountered (A and D), with D being dominant and 
with  subgenotype  distribution  with  D3  predomi-
nance  closest  to  western  Mediterranean  countries 
(Lazarević et al., 2010; Zehender et al., 2008). Re-
cently, the full molecular characterization of the D3 
subgenotype was reported by Stanojević et al. (2011), 
while aim of the present study was to obtain the se-
quence and description of the full genome sequences 
of subgenotypes D1, D2 and A2 from Serbian iso-
lates.
All 5 Serbian isolates clustered with sequences 
from  the  expected  geographic  regions,  those  that 
have significant demographic and historical ties with 
Serbia, such as central and eastern European coun-
tries and Turkey. This is observed for D1 and D2 
clusters, where the Serbian isolates belong to differ-
ent clusters from isolates originating in Asia or the 
Far East. In the case of A genotype isolates, both of 
them were clustered with A2 subgenotype isolates, 
known to be a “European” subgenotype.
Results revealed by phylogenetic analysis of the 
full genome sequences of 5 isolates were generally in 
accordance with data about genotypes and subgeno-
types previously obtained by partial S gene-sequenc-
ing of the same isolates. Only in the case of one iso-
late, previously identified as D3, and in this study as 
D1, was subgenotyping by partial sequencing proved 
to be inaccurate. This method is reliable for the de-
tection of genotypes since the S gene sequence coding 
for small S protein has many genotype-specific spots, 
but differentiation between subgenotypes based on 
sequence clustering in the phylogenetic tree cannot 
be perfectly accurate when the examined sequence is 
not long enough. Therefore, subgenotype distribution 
based on full genome sequences can perhaps show 
the higher frequency of D1, particularly because this 
is the prevalent subgenotype in Asia Minor (Norder 
et al., 2004, Bozdayi et al., 2005), a region with im-
portant historical connections to Serbia.
The clinically relevant mutations were not very 
frequent in the studied sequences since the isolates 
chosen were from therapy-naïve patients and mostly 
HBeAg-positive in order to avoid nucleotide changes 
derived from these factors. The absence of any RT 
mutation known to be associated with resistance to 
antiviral therapy was not unexpected since in most 
cases these mutations need drug-induced selective 
pressure to develop. 
HBeAg-negative chronic hepatitis B evolves in 
the natural history of chronic HBV infection and is 
linked with the selection of nonproducing HBeAg 
but replication-competent HBV mutants. Although 
it  was  first  believed  to  prevail  in  the  Mediterra-
nean area, this form of chronic hepatitis, accord-
ing  to  recent  data,  appears  to  be  more  common 
and is gradually becoming the predominant form 
in all countries (Hadziyannis and Papatheodoridis, 
2006). Mutations responsible for HBeAg-negative 
hepatitis belong to the BCP region of the X gene 
and Pre-C region, and are very common among the 
isolates  of  chronically  infected  patients  in  Serbia COMPLETE HBV GENOMES FROM SERBIA 1325
(Lazarević 2008). Only one HBeAg-positive geno-
type  D  isolate  displayed  compensatory  mutation 
T1753A in the BCP region. This mutation, unlike 
A1762T and G1764A mutations, is not responsible 
for decreased expression of HBeAg, but usually ac-
companies it and is associated with an increased 
replication fitness of the strain. Therefore, the pres-
ence of this mutation alone can perhaps be the first 
phase in transformation of the strain to HBeAg-
nonproducing. The other genotype D isolate, origi-
nating  from  an  HBeAg-negative  patient,  showed 
the very common Pre-C mutation G1896A, which 
transforms codon 28 into a stop codon and leads to 
the abolishment of HBeAg production. This muta-
tion is particularly common in genotype D isolates 
due to the specific nucleotide sequence that allows 
the stabile structure of epsilon pgRNA and effective 
replication, even in the presence of this mutation 
(Key and Zoulim, 2007).
Mutations within the S gene, particularly within 
the region called “a” determinant (aa124–147), caused 
by selection or natural variation, can affect the anti-
genicity of HBsAg and lead to false-negative results 
by assays for HBsAg; or it can have clinical implica-
tions, such as evasion of anti-HBV immunoglobulin 
(HBIg) therapy or vaccine-induced immunity. Muta-
tions found in the examined isolates were all outside 
of this region and were not associated with any clini-
cal and diagnostic problems.
The results of this study are in accordance with 
country’s geographic position, since the first com-
plete  genome  sequences  of  D1,  D2  and  A2  HBV 
isolates show characteristics similar to HBV isolates 
from other European and Middle East countries. The 
results revealed may enable further characterization 
of HBV strains circulating in the Balkans.
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